Chemotherapy Regimen 2

DRUG4 trials

Sponsors

Syndax Pharmaceuticals, Biotheus Inc., Pfizer

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaAcute Undifferentiated LeukemiaAdvanced Non-Small Cell Lung CancerCRC (Colorectal Cancer)CarcinomaCarcinoma, Non-Small-Cell Lung

Phase 1

A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

CompletedNCT05326516

Syndax PharmaceuticalsAcute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia +3

Start: 2022-03-09End: 2024-07-29Updated: 2024-08-13

Phase 2

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Not yet recruitingNCT07133750

Biotheus Inc.CRC (Colorectal Cancer)

Start: 2025-08-31End: 2029-08-31Target: 40Updated: 2025-08-21

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Not yet recruitingNCT07489066

PfizerCarcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer (NSCLC) +6

Start: 2026-04-01End: 2031-08-05Target: 120Updated: 2026-03-23

Phase 3

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

RecruitingNCT07222566

PfizerAdvanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) +3

Start: 2026-01-06End: 2032-08-26Target: 1410Updated: 2026-01-23